Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics (NASDAQ: FATE) announced on November 1, 2025 that it granted restricted stock units representing 34,700 shares to three newly hired non-executive employees as inducement awards under its Amended and Restated Inducement Equity Plan.
The grants were approved by the Compensation Committee and were made in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years with 25% vesting on each anniversary of the grant date, subject to continuous employment through each vesting date.
Fate Therapeutics (NASDAQ: FATE) ha annunciato il 1 novembre 2025 di aver concesso unità azionarie soggette a restrizioni rappresentanti 34.700 azioni a tre nuovi dipendenti non esecutivi assunti come premi di induzione ai sensi del suo Piano di Inducement Equity, come modificato e integrato.
Le assegnazioni sono.state approvate dal Compensation Committee e sono state emesse in conformità con la Regola di quotazione Nasdaq 5635(c)(4). Le RSU si vestono nell'arco di quattro anni, con il 25% che matura ad ogni anniversario della data di assegnazione, soggetto al mantenimento dell'impiego fino a ciascuna data di maturazione.
Fate Therapeutics (NASDAQ: FATE) anunció el 1 de noviembre de 2025 que concedió unidades de acciones restringidas que representan 34.700 acciones a tres nuevos empleados no ejecutivos contratados como premios de inducción bajo su Piano de Inducement Equity, modificado y restablecido.
Las concesiones fueron aprobadas por el Comité de Compensación y se realizaron de conformidad con la Regla de Listado de Nasdaq 5635(c)(4). Las RSU se consolidan a lo largo de cuatro años con un 25% de vesting en cada aniversario de la fecha de concesión, sujeto al continuo empleo hasta cada fecha de vesting.
Fate Therapeutics (NASDAQ: FATE)가 2025년 11월 1일에 자사의 개정 및 재정의 Inducement Equity Plan에 따라 신규 채용 비임원 직원 3명에게 34,700주의 제한 주식단위(RSU)를 수여했다고 발표했습니다.
이 수여는 보상위원회가 승인했으며 나스닥 상장 규칙 5635(c)(4)에 따라 이루어졌습니다. RSU는 4년에 걸쳐 가속될 예정이며 매년의 생일에 25%가 vesting되며, 각 vesting 날짜까지 지속적으로 고용되어야 합니다.
Fate Therapeutics (NASDAQ: FATE) a annoncé le 1er novembre 2025 qu’elle avait accordé des unités d’actions restreintes représentant 34 700 actions à trois nouveaux employés non cadres en tant que primes d’induction au titre de son Pla n d’Inducement Equity, tel que modifié et révisé.
Les subventions ont été approuvées par le Comité de rémunération et ont été effectuées conformément à la Règle de cotation Nasdaq 5635(c)(4). Les RSU se vestent sur une période de quatre ans avec 25% qui vestent à chaque anniversaire de la date d'octroi, sous réserve d’un emploi continu jusqu’à chaque date de vesting.
Fate Therapeutics (NASDAQ: FATE) gab am 1. November 2025 bekannt, dass es restriktive Aktienzuteilungen in Form von Restricted Stock Units 34.700 Aktien an drei neue, nicht leitende Mitarbeiter als Anreizzuteilungen gemäß seinem Geänderte und überarbeitete Inducement Equity Plan gewährte.
Die Gewährungen wurden vom Vergütungsausschuss genehmigt und erfolgten gemäß Nasdaq Listing Rule 5635(c)(4). Die RSUs vesten über vier Jahre mit jeweils 25% Vesting am jeweiligen Jahrestag des Zuteilungsdatums, vorbehaltlich einer kontinuierlichen Beschäftigung bis zu jedem Vesting-Datum.
Fate Therapeutics (NASDAQ: FATE) أعلنت في 1 نوفمبر 2025 أنها منحت وحدات أسهم مقيدة تمثل 34,700 سهم لثلاثة موظفين جدد غير تنفيذيين كجوائز حافزة بموجب خطتها المعدلة والمنقحة Inducement Equity Plan.
تمت الموافقات من قبل لجنة التعويض وكانت وفق قاعدة إدراج ناسداك 5635(c)(4). يتم vesting RSU على مدى أربع سنوات مع استحقاق 25% في كل ذكرى من تاريخ المنح، رهناً باستمرارية العمل حتى تاريخ الاستحقاق.
- None.
- None.
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on November 1, 2025 the Company granted restricted stock units (RSUs) representing 34,700 shares of its common stock to three newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ
How many shares did Fate Therapeutics (FATE) grant as inducement awards on November 1, 2025?
What is the vesting schedule for the FATE RSU inducement awards granted November 1, 2025?
Under which plan and Nasdaq rule were the FATE inducement awards granted?
Who approved the November 1, 2025 RSU grants at Fate Therapeutics (FATE)?
Do the FATE RSU inducement awards apply to executive employees?
What condition must be met for each FATE RSU vesting installment?
